SCHEMBL3592914

SCHEMBL3592914

[NH]c1cccc2c1NC(=O)CS2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.41
MAOB P27338 4/20 0.41
EPHX2 P34913 1/20 0.41
GSK3A P49840 2/20 0.38
GSK3B P49841 2/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
HTT P42858 2/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
KIF11 P52732 1/20 0.36
ADAMTS5 Q9UNA0 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3592916 0.79 MAOA (0.41) MAOAMAOBEPHX2GSK3AGSK3B
SCHEMBL11275562 0.79 MAOA (0.41) MAOAMAOBEPHX2GSK3AGSK3B
SCHEMBL10764795 0.79 AHR (0.51) MAOAMAOBEPHX2GSK3AGSK3B
SCHEMBL2433215 0.75 HTT (0.48) MAOAMAOBEPHX2HTTALDH1A1
SCHEMBL11447667 0.73 LMNA (0.52) MAOAMAOBEPHX2GAAALDH1A1
SCHEMBL3606772 0.73 MAOA (0.42) MAOAMAOBEPHX2GSK3AGSK3B
SCHEMBL9161477 0.72 MAOA (0.36) MAOAMAOBEPHX2GSK3AGSK3B
SCHEMBL13323 0.69 ALDH1A1 (0.60) MAOAMAOBEPHX2GAAHTT
SCHEMBL7270821 0.69 LMNA (0.43) MAOAMAOBEPHX2HTTLMNA
SCHEMBL30418617 0.68 BRD4 (0.37) MAOAMAOBEPHX2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 MAOA 1461/4885MAOB 1349/4885EPHX2 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.